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Background: Cancer immunotherapy requires proper manipulation of the immune system, lymphocytes in particular,
in order to identify and destroy the cancer cells as non-self. In this study we investigated the effect of the flavonoid
present in green tea, namely epigallocatechin-3-gallate (EGCG), on the proliferation of, and IFN-γ production by,
peripheral blood mononuclear cells (PBMC) from breast cancer patients stimulated with a mitogen, anti-CD3 and the
common breast cancer peptides Her-2/neu, and p53.
Methods: Blood samples were collected from 25 patients with breast cancer at the Kuwait Cancer Control Centre
(KCCC). The patients were newly diagnosed, and had not undergone any treatment or surgery at the time of sample
collection. The control group consisted of 25 healthy women age-matched (±5 years) to the patients. PBMC were
isolated from the patients and controls, and were cultured separately with the mitogen PHA, anti-CD3 antibodies, and
Her-2/neu and p53 in the presence or absence of standardized doses of EGCG. The degree of proliferation and
interferon-γ [IFN-γ) release were then analyzed.
Results: EGCG significantly suppressed the proliferation of PBMC in response to stimulation separately with (i) the
mitogen, (ii) anti-CD3, and (iii) the cancer antigen peptides. IFN-γ production was also significantly suppressed by EGCG
in vitro.
Conclusions: EGCG appears to have an immunosuppressive effect on the proliferation of PBMC, indicating that EGCG
is worth exploring for immunomodulatory effects in autoimmune diseases and tissue transplantation.
Keywords: EGCG, PBMC, IFN-γ, Green teaBackground
Green tea contains polyphenols, particularly catechins,
the most abundant of which is Epigallocatechin-3-gallate
(EGCG) [1-4]. It has been reported that EGCG can exert
in vitro antitumor effects in various types of cancer, such
as cancer of the breast, esophagus, prostate, skin, stom-
ach, lung, colon, and pancreas [1,5-7]. Studies have
shown that EGCG mediates its anti-cancer effect by
regulating cancer cell angiogenesis and metastasis [1,2,8].
Another important characteristic of EGCG is its rela-
tively low systemic toxicity [9,10]. Thus, EGCG has* Correspondence: dadaland@gmail.com
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immunostimulant in cancer therapy [11].
Several investigations have highlighted the possible
role of the immune system in cancer treatment. These
include studies which showed a positive correlation be-
tween tumor-infiltrating T lymphocytes and patient sur-
vival, and where tumor-specific T cell responses were
found in individuals with premalignant lesions and in
patients with recurrent primary tumors [12-20]. Cyto-
toxic T lymphocytes (CTLs) isolated from some of these
patients, cultured in vitro with whole tumor lysate or
with dendritic cells (DCs) pulsed with tumor antigens/
peptides, and then returned to the cancer patients were
found to be capable of targeting the tumor causing its
partial or complete regression [21]. An important
principle in cancer immunotherapy is to get CD8+ CTLstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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the tumor site. This generally requires help from T
helper lymphocytes (CD4+ T cells), and from antigen-
presenting cells (APCs) like the DCs.
Studies investigating the effect of EGCG on the im-
mune system have yielded varying results. Kang and col-
leagues reported that combining HPV DNA vaccine with
oral EGCG intake resulted in an enhanced tumor-
specific T-cell immune response, and an enhanced anti-
tumor effect in mice injected with three tumor cell lines
(TC-1, B16, and B16E7) [22]. This also resulted in a high
cure rate, with a long-term antitumor protection in the
cured mice. In fact, the cured animals were capable of
rejecting a challenge with E7-expressing tumors like TC-
1 and B16E7 weeks after the combined therapy, and they
showed significant antigen-specific immune responses
[22]. On the other hand, Kawai and co-workers reported
that EGCG exerted down-regulation of CD11b expres-
sion on CD8+ T cells [23]. Being a member of the α-
chain integrin family, CD11b can form a complex with
β2-integrin known as Mac-1. CD11b is often expressed
on monocytes, neutrophils, a subset of CD8+ T cells,
and natural killer cells, and has a key role in helping
lymphocytes migrate from the intravascular space into
the target tissues [24,25]. Accordingly, the presence of
circulating and interstitial CD8+CD11b+ T cells repre-
sents recently-activated effector cells [26,27].
Given the fact that the effect of EGCG on lymphocytes
is still open to further investigation, we sought to ob-
serve the effect of EGCG on the proliferation of, and
IFN-γ production by, peripheral blood mononuclear
cells from newly-diagnosed breast cancer patients.
Methods
Ethics approval
The study was approved by the Ethics Committees of
the Faculty of Medicine, Kuwait University. Both pa-
tients and controls gave informed consent after receiving
a detailed description of the study.
Blood samples
Six milliliters of venous blood was collected in heparinized
tubes from both patients and controls. Blood samples
were transported directly to the Cellular Immunology La-
boratory at the Faculty of Medicine, Kuwait University.
Separation of peripheral blood mononuclear cells (PBMC)
and stimulation of cells were performed within two hours
of withdrawal of blood.
Procedure
PBMC were separated by Ficoll-hypaque density gradient
centrifugation, suspended in RPMI medium containing
10% fetal calf serum, aliquoted into 96 well tissue culture
plates at a density of 105 cells per well, and thenchallenged with the breast cancer antigen peptides (p53: se-
quence: TYSPALNKMF; Her-2/neu: sequence: KIFGSLAFL;
JPT Peptide Technologies, Germany) for six days, or with
5 μg/ml of the mitogen phytohemagglutinin (PHA) (Sigma
Aldrich, St. Louis, USA) for a period of four days. For
stimulation with anti-CD3 antibodies, tissue culture plates
were first coated overnight with anti-CD3 antibodies
(Bender MedSystems, Vienna, Austria) followed by wash-
ing with sterile phosphate buffered saline (PBS). PBMC
were then aliquoted into the wells of the plates. Cell pro-
liferation was measured by estimating the incorporation
of 3H-thymidine (GE Healthcare, Uppsala, Sweden). Cul-
ture supernatants were collected 4 days following activa-
tion with mitogen or anti-CD3 and after 6 days following
activation with breast cancer antigen peptides in order to
measure the levels of IFN-γ by ELISA. PBMC were treated
in triplicates as shown below:
1) PBMC + tissue culture medium alone (negative
control).
2) PBMC +Mitogen or Antigen or anti-CD3 alone
(positive control).
3) PBMC +Antigen or Mitogen or anti-CD3 + EGCG.
ELISA for the estimation of IFN-γ
The manufacturer’s protocols (Beckman Coulter, Marseilles,
France) were followed for these assays, which are based
on the antibody sandwich principle; samples and stan-
dards were first incubated with a solid phase monoclonal
antibody which captures the specific cytokine present.
The solid phase-bound cytokine was then incubated with
a second antibody such as biotinylated anti-cytokine anti-
body. The resulting antigen-antibody complexes were
then incubated with a streptavidin-enzyme conjugate after
which the substrate and chromogen were added. The
resulting color development, which is directly propor-
tional to the amount of the cytokine present in the sample
and standards, was stopped after 5 minutes. Samples were
tested in triplicate, and the absorbance values read using
an ELISA Reader. Accurate sample concentrations of cy-
tokines were determined by comparing their respective
absorbencies with those obtained for the reference stan-
dards plotted on a standard curve.
Statistical analysis
Data were analyzed using ANOVA (SPSS statistical
package for Windows). All data are expressed as mean ±
Standard Error of the mean (SEM). A difference was
considered significant if the P value was ≤ 0.05.
Results
Initial standardization of optimal EGCG concentration
PBMC were stimulated with PHA or anti-CD3 or the
breast cancer peptides in the presence and absence of
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with radioactive thymidine for 18 hours; cells were then
harvested and the radioactivity estimated. In order to
find the optimal concentration of EGCG, it was tested at
seven concentrations 50 μg/ml, 10 μg/ml, 5 μg/ml, 1 μg/ml,
0.5 μg/ml, 0.25 μg/ml and 0.125 μg/ml. PBMC from five
breast cancer patients were exposed to the mitogen in the
absence and presence of EGCG. A significant suppression
of PBMC was observed with an EGCG concentration of
50 μg/ml (p < 0.0001), and to a lesser extent with 10 μg/ml
(p < 0.01). Lower concentrations of EGCG did not show
any suppression.
PBMC were incubated either with anti-CD3 alone, or
with anti-CD3 along with different concentrations of
EGCG. The results showed that an EGCG concentration
of 50 μg/ml induced a significant suppression of PBMC
proliferation (p < 0.0001), which was also observed at an
EGCG concentration of 10 μg/ml (p < 0.01). No signifi-
cant suppression of proliferation was observed at lower
EGCG concentrations.
The two breast cancer antigen peptides Her-2/neu and
p53 were tested at five different concentrations, namely
5 μg/ml, 10 μg/ml, 20 μg/ml, 40 μg/ml, and 80 μg/ml.
EGCG suppressed the proliferation of PBMC in re-
sponse to both breast cancer antigen peptides; this sup-
pression was stronger when EGCG was tested at 50 μg/ml
(p < 0.0001), and to a lesser extent when tested at 10 μg/ml
(p < 0.01). No suppression was seen when EGCG was used
at lower concentrations. Accordingly, we proceeded to test
the samples obtained from the 25 breast cancer patients
and 23 healthy age-matched controls using two concen-
trations of EGCG, namely 50 μg/ml and 10 μg/ml. The
data presented here pertain to the EGCG 50 μg/ml and
experiments. Data pertaining to the EGCG 10 μg/ml ex-
periments are not presented, but will be provided upon re-
quest. Also, we report here results pertaining to the
peptide concentration of 80 μg/ml experiments. ResultsTable 1 The effect of epigallocatechin-3-gallate (EGCG) on bre
proliferation and IFN-γ production




Cell control Mitogen alone Mitogen + EGCG Mitogen alone M
69 ± 7 11289 ± 1637 33 ± 4 172 ± 26
Cell control Anti-CD3 alone Anti-CD3 + EGCG Anti-CD3 alone A
199 ± 29 39252 ± 4182 73 ± 14 262 ± 49
Cell control Her-2/neu alone Her-2/neu + EGCG Her-2/neu alone H
101 ± 8 432 ± 79 40 ± 6 4.3 ± 0.7
Cell control p53 alone p53 + EGCG p53 alone
72 ± 9 972 ± 191 39 ± 5 9 ± 1
cpm: Counts per minute; SEM: Standard error from the mean; Mitogen: phytohemaggl
Her-2/neu and p53 (80 μg/ml). All results obtained by EGCG were significant at p < 0.0pertaining to the peptide concentration of 40 μg/ml will
be provided upon request.
Effect of EGCG on mitogen-induced proliferation and
IFN-γ release
As shown in Table 1, a significant suppression of prolif-
eration of PBMC against PHA (shown as cpm of thymi-
dine uptake) was detected in the presence of an EGCG
concentration of 50 μg/ml (p = 0.0001). The stimulation
index calculated as counts per minute of test culture di-
vided by counts per minute of control culture was also
significant (p = 0.0001). EGCG at a concentration of
50 μg/ml also suppressed IFN-γ production (p = 0.003).
No significant differences in stimulation indices and
IFN-γ production were observed between breast cancer
patients and normal healthy controls.
Effect of EGCG on anti-CD3-induced proliferation and
IFN-γ release
The results obtained with anti-CD3 were similar to
those seen with PHA. As shown in Table 1, EGCG sig-
nificantly suppressed the proliferation of PBMC against
anti-CD3 (p = 0.003), as measured by thymidine uptake,
when it was added to the culture at a concentration of
50 μg/ml. Similar observations were made with stimula-
tion indices (p = 0.003), and IFN-γ production (p =
0.003). No significant differences were observed in the
extent of suppression between cancer patients and healthy
controls.
Effect of EGCG on Her-2/neu-induced proliferation and
IFN-γ release
The effect of EGCG on breast cancer antigen peptide-
induced proliferation was tested in the 25 breast can-
cer patients. EGCG significantly suppressed Her-2/neu
(80 μg/ml)-peptide-induced proliferation (thymidine up-
take), when added at a concentration of 50 μg/ml (p =ast cancer peripheral blood mononuclear cells (PBMC)
[SI] of PBMCs)
M)
IFN-γ release by PBMCs
(pg/ml ± SEM)
itogen + EGCG Cell control Mitogen alone Mitogen + EGCG
0.4 ± 0.04§ 53 ± 8 2153 ± 454 38 ± 12§
nti-CD3 + EGCG Cell control Mitogen alone Anti-CD3 + EGCG
1 ± 0.05 54 ± 42 24508 ± 717 10 ± 4
er-2/neu + EGCG Cell control Her-2/neu alone Her-2/neu + EGCG
0.4 ± 0.07 13 ± 6 62 ± 12 28 ± 9
p53 + EGCG Cell control p53 alone p53 + EGCG
0.4 ± 0.06 52 ± 8 109 ± 11 33 ± 5
utinin (PHA); EGCG (50 μg/ml); IFN-γ: Interferon gamma; pg/ml: Picogram per ml.
1, as indicated by the symbol “§”.
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peptide concentration was 40 μg/ml (p = 0.002).
Stimulation indices showed significant (p =0.002) sup-
pression similar to those seen with thymidine uptake,
when EGCG was used at a concentration of 50 μg/ml in
the presence of 80 μg/ml of the Her-2/neu antigen pep-
tide (Table 1). Again, a similar trend was observed when
the peptide concentration was 40 μg/ml (p = 0.002).
As far as production of IFN-γ by stimulated PBMC is
concerned, EGCG induced significant suppression at a
concentration of 50 μg/ml in the presence of 80 μg/ml
(p = 0.04) and 40 μg/ml (p = 0.05) of the Her-2/neu anti-
gen peptide (Table 1).
Effect of EGCG on p53-induced proliferation and IFN-γ
release
As shown in Table 1, significant suppression was seen
with the p53 antigen peptide. Proliferation of PBMC in-
duced with 80 μg/ml of the peptide was significantly
suppressed when EGCG was added at 50 μg/ml (p =
0.002). Likewise, EGCG suppressed the proliferation of
PBMC (p = 0.002), when PBMC were stimulated with
40 μg/ml of the peptide.
Stimulation indices showed similar suppression; PBMC
stimulated with p53 at 80 μg/ml were suppressed when
EGCG was added at 50 μg/ml (p = 0.002) (Table 1). Simi-
larly, PBMC stimulated with 40 μg/ml of the p53 antigen
peptide were significantly suppressed when EGCG was
added at 50 μg/ml (p = 0.002).
Finally, the production of IFN-γ by PBMC stimulated
with 80 μg/ml of the p53 peptide antigen was signifi-
cantly suppressed when EGCG was added at 50 μg/ml
(p = 0.009) (Table 1). EGCG also significantly suppressed
IFN-γ production (p = 0.05) in the presence of the p53
peptide antigen at a concentration of 40 μg/ml.
Effect of EGCG on cell viability
To ascertain whether EGCG brings about an inhibition
of cell proliferation by killing peripheral blood cells, we
measured cell viability in nine samples at random using
the Trypan Blue Dye Exclusion Test. This test is based
on the principle that viable cells do not allow uptake of
the dye, while the dye enters dead cells which then ap-
pear blue under the microscope. We measured the via-
bility of cells cultured with medium alone, with EGCG,
and with PHA plus EGCG at concentrations ranging
from 1 μg/ml to 50 μg/ml. Cell viability in cultures with
medium alone was 99-100%, and viability in cultures
with EGCG was 98-100%. Cells in cultures with PHA
alone had a viability of 95-98%, while those in cultures
with PHA and EGCG at different concentrations also
had a viability ranging from 95 to 98%. These experi-
ments indicate that EGCG, at least at the concentrations
tested here, does not affect cell viability. Therefore, wesuggest that the decrease in cell proliferation and IFN-γ
production is related to suppression rather than to a
cytotoxic effect.
Discussion
The benefit of the antioxidant component of green tea
on human health, especially in preventing cancer devel-
opment, has been the subject of investigation over the
last decade. Drinking green tea has been reported to sig-
nificantly decrease the risk of developing gastrointes-
tinal, breast, epithelial ovarian, and prostate cancer, to
name a few conditions [28-33]. In addition to cancer
prevention, the therapeutic usage of green tea in treating
cancer has also been studied, and has yielded promising
results in prostate, breast, and lung cancer, as well in
chronic lymphocytic leukemia [34].
Cancer immunotherapy relies on stimulating the im-
mune system of the patient against cancer cell peptide
antigens. For this to take place, immune cells must go
through a cascade of events involving antigen recogni-
tion, presentation, and destruction of the cancer cells ex-
pressing these antigens. The immune cells must also
prevent the attempts of the cancer cells to evade their
surveillance. In this study, we investigated the possibility
of stimulating the proliferation of PBMC isolated from
breast cancer patients against two common breast can-
cer antigens Her-2/neu and p53, using EGCG in culture.
The most abundant catechin in green tea is EGCG,
which represents around 50% of catechins found in
green tea. Therefore, any effect of green tea extract is at-
tributed to this catechin. We based our investigation on
the demonstration that consumption of green tea has
already been shown to yield positive results in certain
types of human cancer, as described earlier. Therefore, if
EGCG is capable of enhancing the proliferation of
PBMC, this could be further investigated in relation to
using it as part of peptide-based vaccine immunotherapy
of cancer. Surprisingly, our results showed that EGCG
induced suppression of proliferation (measured by both
thymidine uptake and stimulation index) of PBMC when
used at a standardized dose of 50 μg/ml and 10 μg/ml.
No significant suppression was observed at doses lower
than 10 μg/ml. Such suppression was also observed in
the amount of IFN-γ released in culture. We have also
demonstrated that that the results obtained in this study
were due to suppression of proliferation of PBMC and
not due to cytotoxicity exerted by EGCG.
Our results are in accord with those reported by Wu
and colleagues, who investigated the effect of EGCG on
immune cells isolated from mice [35]. The authors re-
ported that proliferation of T cells was inhibited by
EGCG at physiologically relevant concentrations. EGCG
inhibited T cell division and cell cycle progression in a
dose-dependent manner, and no cytotoxicity or apoptosis
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presence of EGCG resulted in higher IL-2 accumulation
and lower IL-2 receptor expression, thus implying an im-
peded IL-2/IL-2 receptor signaling [35]. Other studies
have also demonstrated the suppressive effect of EGCG
on the immune system. Aktas and co-workers reported
that EGCG administered orally to mice significantly abro-
gated proliferation and TNF-α production of T cells [36].
The authors also reported the induction of CD4+ T cell
cycle arrest resulting in down-regulation of cyclin-
dependent kinase 4. Further analysis revealed that the
interference with T cell growth and function was mediated
by the blockade of the catalytic activities of the 20S/26S
proteasome complex, resulting in intracellular accumula-
tion of IkB-α and subsequent inhibition of NFkB activation
[36]. Hu and colleagues demonstrated that EGCG signifi-
cantly inhibited the proliferation of B and T cells in cul-
ture [37]. Similarly, Wilasrusmee and co-workers and
Zvetkova and colleagues reported that green tea extract
inhibited the proliferation of murine lymphocytes in vitro,
and the production of neopterin, a marker for cellular im-
munity by human PBMC, respectively [38,39]. Other stud-
ies have demonstrated suppression of maturation of
mouse bone marrow-derived dendritic cells (DCs), and
antigen-presenting cells derived from human monocytes
when cultured with EGCG [40,41]. T cells co-cultured
with EGCG-treated DCs also exhibited decreased pro-
liferation EGCG [40,41]. In a recent study conducted
by Pae and colleagues, the authors confirmed a direct
inhibitory effect of EGCG on T cells, and that this
was more pronounced in CD4+ T cells, as compared
to CD8+ T cells [42]. EGCG also inhibited accessory
and antigen-presenting cell function, which further strength-
ened its inhibition of T cells. More recent studies have fur-
ther demonstrated the suppressive role of EGCG on the
various arms of the immune system in cancer cases
[43-49]. In a study conducted by Mukherjee and col-
leagues, the authors reported that treatment with EGCG
resulted in the inhibition of cytokine and chemokine gene
induction, cell migration, and activity of MMP-9 and −2
in prostate cancer [43]. Ren and co-workers demonstrated
a dose-dependent suppression of migration of lipopoly-
saccharide (LPS)-activated macrophagic RAW264.7 cells
[44]. Chen and colleagues reported that some anti-
inflammatory phytochemicals like EGCG appear to modu-
late the tumor microenvironment by repressing NF-kappaB
(NF-κB, a proinflammatory transcription factor), and inhi-
biting pro-inflammatory cytokines like IL-6 and TNF-α in
epithelial ovarian cancer [45]. In a study conducted on
melanoma, Ellis and co-workers demonstrated a signifi-
cant reduction in the levels of cyclooxygenase (COX)-2,
prostaglandin (PG) E(2), and PGE(2) receptors (EP2 and
EP4) when EGCG was administered [46]. Similar results
were reported by Singh and Kativar [47]. Hoffmann andcolleagues reported both dose-dependent and time-
dependent down-regulation of IL-1 (a key player in
inflammation-associated cancer development) by EGCG
in pancreatic cancer [48]. Kürbitz and co-workers re-
ported that green tea catechins like epicatechin gallate
and catechin gallate were superior to EGCG in inhibiting
TNFα-induced activation of NF-κB and consequently se-
cretion of pro-inflammatory and invasion promoting pro-
teins like uPA and IL-8, when cultured with pancreatic
tumor cells [49].
Conclusion
Our results demonstrate that EGCG has an inhibitory
effect on the proliferation of PBMC as well as the pro-
duction of IFN-γ by PBMC isolated from breast cancer
patients when cultured with the breast cancer peptide
antigens Her-2/neu and p53 as well as with the mitogen
PHA and with anti-CD3 antibodies. Although such ob-
servations may contradict the use of EGCG in cancer
immunotherapy, it may open the door to further studies
on its use as an immunomodulatory agent in auto-
immune diseases and tissue transplantation.
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